A New Species of \u3ci\u3eNanodacna\u3c/i\u3e Clarke (Lepidoptera: Elachistldae: Agonoxeninae) Feeding on the Seeds of \u3ci\u3eAustrocedrus chilensis\u3c/i\u3e (Cupressaceae) in Andean Argentina

Charaders of the adult, larva, and pupa of Nanodacna allstrocedrella Landry & Adamski, new species, are described and illustrated. The seed-feeding larvae cause damage to Andean Cedar, cipres de la cordillera [Austrocedrus chilcnsis (D. Don.) Fl. & Bout., Cupressaceae] in Chubut Province, Argentina. The species is compared to other species of Nanodacna and to species of Hornoeoprepes Walsingham from the Neotropics. Criteria for its inclusion in Nanodacna and the phylogenetic Significance of characters of immature stages for relationships within the Agonoxeninae are discussed

Two New Species of \u3ci\u3eWockia\u3c/i\u3e Heinemann (Lepidoptera: Urodidae) from Coastal Dry-Forests in Western Mexico

Two new species of Wockia Heinemann, 1870 (Lepidoptera: Urodidae), W. chewbacca and W. mexicana, are described from primary dry-forests in western Mexico. A new host record is reported for the genus from larvae of W. chewbacca feeding on leaves of Casearia nitida (L.) Jacq. (Salicaceae). Several shared genitalic features and DNA barcode similarities suggest a congeneric relationship between the two Mexican species but uncertain generic placement within Urodidae. Scanning electron micrographs of the larva and illustrations of the larva and pupa of Wockia chewbacca are provided, along with illustrations of male and female genitalia of both Mexican species. Three unusual features found in the larval stage are documented for W. chewbacca include; a multi-lobed integument, recurved D2 seta on the shield of T1, and a ‘‘hydroid bush’’ consisting of multiple sensilla trichoidea on the apical turret of the antenna. Locality data indicate the existence of Neotropical elements of Wockia and an expanded distributional range for the genus

Two New Species of \u3ci\u3eWockia\u3c/i\u3e Heinemann (Lepidoptera: Urodidae) from Coastal Dry-Forests in Western Mexico

Two new species of Wockia Heinemann, 1870 (Lepidoptera: Urodidae), W. chewbacca and W. mexicana, are described from primary dry-forests in western Mexico. A new host record is reported for the genus from larvae of W. chewbacca feeding on leaves of Casearia nitida (L.) Jacq. (Salicaceae). Several shared genitalic features and DNA barcode similarities suggest a congeneric relationship between the two Mexican species but uncertain generic placement within Urodidae. Scanning electron micrographs of the larva and illustrations of the larva and pupa of Wockia chewbacca are provided, along with illustrations of male and female genitalia of both Mexican species. Three unusual features found in the larval stage are documented for W. chewbacca include; a multi-lobed integument, recurved D2 seta on the shield of T1, and a ‘‘hydroid bush’’ consisting of multiple sensilla trichoidea on the apical turret of the antenna. Locality data indicate the existence of Neotropical elements of Wockia and an expanded distributional range for the genus

A small protein coded within the mitochondrial canonical gene nd4 regulates mitochondrial bioenergetics

BACKGROUND: Mitochondria have a central role in cellular functions, aging, and in certain diseases. They possess their own genome, a vestige of their bacterial ancestor. Over the course of evolution, most of the genes of the ancestor have been lost or transferred to the nucleus. In humans, the mtDNA is a very small circular molecule with a functional repertoire limited to only 37 genes. Its extremely compact nature with genes arranged one after the other and separated by short non-coding regions suggests that there is little room for evolutionary novelties. This is radically different from bacterial genomes, which are also circular but much larger, and in which we can find genes inside other genes. These sequences, different from the reference coding sequences, are called alternatives open reading frames or altORFs, and they are involved in key biological functions. However, whether altORFs exist in mitochondrial protein-coding genes or elsewhere in the human mitogenome has not been fully addressed. RESULTS: We found a downstream alternative ATG initiation codon in the + 3 reading frame of the human mitochondrial nd4 gene. This newly characterized altORF encodes a 99-amino-acid-long polypeptide, MTALTND4, which is conserved in primates. Our custom antibody, but not the pre-immune serum, was able to immunoprecipitate MTALTND4 from HeLa cell lysates, confirming the existence of an endogenous MTALTND4 peptide. The protein is localized in mitochondria and cytoplasm and is also found in the plasma, and it impacts cell and mitochondrial physiology. CONCLUSIONS: Many human mitochondrial translated ORFs might have so far gone unnoticed. By ignoring mtaltORFs, we have underestimated the coding potential of the mitogenome. Alternative mitochondrial peptides such as MTALTND4 may offer a new framework for the investigation of mitochondrial functions and diseases

DNA barcode library for European Gelechiidae (Lepidoptera) suggests greatly underestimated species diversity

For the first time, a nearly complete barcode library for European Gelechiidae is provided. DNA barcode sequences (COI gene – cytochrome c oxidase 1) from 751 out of 865 nominal species, belonging to 105 genera, were successfully recovered. A total of 741 species represented by specimens with sequences ≥ 500bp and an additional ten species represented by specimens with shorter sequences were used to produce 53 NJ trees. Intraspecific barcode divergence averaged only 0.54% whereas distance to the Nearest-Neighbour species averaged 5.58%. Of these, 710 species possessed unique DNA barcodes, but 31 species could not be reliably discriminated because of barcode sharing or partial barcode overlap. Species discrimination based on the Barcode Index System (BIN) was successful for 668 out of 723 species which clustered from minimum one to maximum 22 unique BINs. Fifty-five species shared a BIN with up to four species and identification from DNA barcode data is uncertain. Finally, 65 clusters with a unique BIN remained unidentified to species level. These putative taxa, as well as 114 nominal species with more than one BIN, suggest the presence of considerable cryptic diversity, cases which should be examined in future revisionary studies.For the first time, a nearly complete barcode library for European Gelechiidae is provided. DNA barcode sequences (COI gene - cytochrome c oxidase 1) from 751 out of 865 nominal species, belonging to 105 genera, were successfully recovered. A total of 741 species represented by specimens with sequences >= 500bp and an additional ten species represented by specimens with shorter sequences were used to produce 53 NJ trees. Intraspecific barcode divergence averaged only 0.54% whereas distance to the Nearest-Neighbour species averaged 5.58%. Of these, 710 species possessed unique DNA barcodes, but 31 species could not he reliably discriminated because of barcode sharing or partial barcode overlap. discrimination based on the Barcode Index System (BIN) was successful for 668 out of 723 species which clustered from minimum one to maximum 22 unique BINs. Fifty-five species shared a BIN with up to four species and identification from DNA barcode data is uncertain. Finally, 65 clusters with a unique BIN remained unidentified to species level. These putative taxa, as well as 114 nominal species with more than one BIN, suggest the presence of considerable cryptic diversity, cases which should be examined in future revisionary studies.Peer reviewe

Author Correction: Implementation, coverage and equity of large-scale door-to-door delivery of Seasonal Malaria Chemoprevention (SMC) to children under 10 in Senegal.

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper

Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline